These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3314448)

  • 1. Low density lipoprotein receptor regulation and the cellular basis of atherosclerosis: implications for nutritional and pharmacologic treatment of hypercholesterolemia.
    Heber D; Koziol BJ; Henson LC
    Am J Cardiol; 1987 Oct; 60(12):4G-8G. PubMed ID: 3314448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
    Tikkanen MJ; Helve E; Nikkilä EA
    Eur Heart J; 1987 Aug; 8 Suppl E():97-101. PubMed ID: 3315684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery, biochemistry and biology of lovastatin.
    Alberts AW
    Am J Cardiol; 1988 Nov; 62(15):10J-15J. PubMed ID: 3055919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individual variation in the effects of dietary cholesterol on plasma lipoproteins and cellular cholesterol homeostasis in man. Studies of low density lipoprotein receptor activity and 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in blood mononuclear cells.
    Mistry P; Miller NE; Laker M; Hazzard WR; Lewis B
    J Clin Invest; 1981 Feb; 67(2):493-502. PubMed ID: 6257763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X.
    Roberts CK; Liang K; Barnard RJ; Kim CH; Vaziri ND
    Kidney Int; 2004 Oct; 66(4):1503-11. PubMed ID: 15458444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
    Liang K; Vaziri ND
    Kidney Int; 2003 Jul; 64(1):192-8. PubMed ID: 12787409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of hepatic low density lipoprotein binding and cholesterol metabolism in normal and homozygous familial hypercholesterolemic subjects.
    Hoeg JM; Demosky SJ; Schaefer EJ; Starzl TE; Brewer HB
    J Clin Invest; 1984 Feb; 73(2):429-36. PubMed ID: 6321555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein fractions and receptors: a role for probucol?
    Bilheimer DW
    Am J Cardiol; 1986 Jun; 57(16):7H-15H. PubMed ID: 3637051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing hepatic cholesterol 7alpha-hydroxylase reduces plasma cholesterol concentrations in normocholesterolemic and hypercholesterolemic rabbits.
    Xu G; Salen G; Shefer S; Ness GC; Nguyen LB; Tint GS; Parker TS; Roberts J; Batta AK; Chen TS; Zhao Z; Kong X
    Hepatology; 1996 Oct; 24(4):882-7. PubMed ID: 8855192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of cyclosporine on HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions.
    Vaziri ND; Liang K; Azad H
    J Pharmacol Exp Ther; 2000 Aug; 294(2):778-83. PubMed ID: 10900260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
    Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
    Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial hypercholesterolemia: dissection of a receptor disease.
    Schneider WJ
    Z Kardiol; 1990; 79 Suppl 3():3-7. PubMed ID: 2099041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    al Rayyes O; Wallmark A; Florén CH
    Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
    Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
    J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [LDL receptors].
    Ducobu J
    Rev Med Brux; 1990 Dec; 11(10):481-92. PubMed ID: 2293288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.
    Jacobson TA
    Am J Cardiol; 1996 Sep; 78(6A):32-41. PubMed ID: 8875973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.